• Contemporary ClinicContemporary Clinic
  • OTC GuideOTC Guide
  • Pharmacy Times
  • PTCEPTCE
  • Pharmacist Moms GroupPharmacist Moms Group
News
All News
FDA Updates
Press Releases
Media
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conferences
Conference Coverage
Conference Listing
Publications
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
Clinical
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Events
Upcoming Events
Upcoming Webinars
CE
Resources
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
logo
Spotlight
Community/RetailHospitalOncologyPharmacy TechnicianStudent
Clinical Role
Community/RetailHospitalOncologyPharmacy TechnicianSpecialty PharmacyStudent
Clinical
CoronavirusBrain HealthCardiovascular HealthDermatologyDiabetesFluHeart FailureHepatitis/MASHImmunizationMigrainePneumococcalVitamins and Supplements
Supplement Spotlight
October 2023 Pharmacy Technician Edition
All News
FDA Updates
Press Releases
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conference Coverage
Conference Listing
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Upcoming Events
Upcoming Webinars
CE
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
Advertisement

CLINICAL ROLE -

Community/Retail
| Hospital
| Oncology
| Pharmacy Technician
| Student

Article

September 3, 2015

FDA Approves Drug for Chemotherapy-Related Nausea

Author(s):

Davy James, Managing Editor

Varubi prevents nausea and vomiting associated with vomit-inducing cancer chemotherapy.

Varubi prevents nausea and vomiting associated with vomit-inducing cancer chemotherapy.

The FDA on Wednesday approved a new option for patients with cancer who suffer from sickness caused by chemotherapy.

Rolapitant (Varubi) prevents delayed phase nausea and vomiting associated with chemotherapy during cancer treatment. Varubi is administered in tablet form to adults in combination with other antiemetic agents to prevent nausea and vomiting from initial and repeat courses of emetogenic and highly emetogenic cancer chemotherapy.

“Chemotherapy-induced nausea and vomiting remains a major issue that can disrupt patients' lives and sometimes their therapy,” said Amy Egan, MD, MPH, deputy director of the Office of Drug Evaluation III in the Center for Drug Evaluation and Research. “Today’s approval provides cancer patients with another treatment option for the prevention of the delayed phase of nausea and vomiting caused by chemotherapy.”

Nausea and vomiting can last from 24 hours to up to 120 hours following the start of chemotherapy, which can result in weight loss, dehydration, and malnutrition. Varubi was approved as a substance P/neurokinin-1 (NK-1) receptor antagonist. NK-1 receptors activate to play the main role in sickness from certain cancer chemotherapies, specifically in the delayed phase.

Varubi inhibits the CYP2D6 enzyme responsible for metabolizing certain drugs. Varubi is contraindicated with the drug thioridazine because use of the 2 drugs together could increase the amount of thioridazine in the blood, which can cause a potentially serious abnormal heart rhythm.

The approval of Varubi followed 3 randomized, double-blind, controlled clinical trials. The drug was found to be safe and effective in combination with granisetron and dexamethasone compared with a control therapy of placebo, granisetron and dexamethasone.

The combination of Varubi, granisetron, and dexamethasone was administered to 2800 patients on a chemotherapy regimen with highly emetogenic drugs, such as cisplatin and the combination of anthracycline and cyclophosphamide, and moderately emetogenic chemotherapy drugs. Patients treated with Varubi experienced a greater decrease in vomiting and rescue medication usage for nausea and vomiting during the delayed phase compared with patients who received the control therapy.

Common side effects from Varubi include a neutropenia, hiccups, loss of appetite, and dizziness.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Tired scared retiree man holding chest with anginal symptoms, pallor and diaphoresis at home. Suffering male with cardiac origin pain, prexcordial pressure, arrhythmia risk, urgent medical attention - Image credit: DimaBerlin | stock.adobe.com
Image credit: Sebastian Kaulitzki | stock.adobe.com
Magnified bone marrow biopsy showing plasma cells with irregular nuclei and multiple myeloma tumor cells infiltrating normal hematopoietic tissue.
Image credit: Dr_Microbe | stock.adobe.com
Related Content
Advertisement
FDA - U.S Food & Drug Administration
June 18th 2025

Midyear Roundup: FDA’s Novel Oncology Drug Approvals in 2025

Luke Halpern, Assistant Editor
S2. Ep 56: Insights From a Pharmacy Times Peer Exchange: How to Talk the Talk
June 3rd 2025

S2. Ep 56: Insights From a Pharmacy Times Peer Exchange: How to Talk the Talk

Alexandra Gerlach, Associate Editor
Vector Representation of Acute Myeloid Leukemia Cells
June 18th 2025

Sequencing of Liposomal Daunorubicin/Cytarabine Versus Hypomethylating Agents Plus Venetoclax for Secondary Acute Myeloid Leukemia

Alan Flores, PharmD Jose Tinajero, PharmD, BCOP Dat Ngo, PharmD
Insights from a Pharmacy Times Peer Exchange: Toxicity Monitoring and Management in Real-World Settings
May 28th 2025

Insights from a Pharmacy Times Peer Exchange: Toxicity Monitoring and Management in Real-World Settings

Alexandra Gerlach, Associate Editor
Nurse -- Image credit: Rawpixel.com | stock.adobe.com
June 17th 2025

The Value of a Medically Integrated Pharmacy to Maximize Cost Avoidance and Reduce Waste of Oral Oncolytic Medications

Douglas Braun, PharmD, CSP, RPh
a microscope view of bone marrow showing the presence of abundant mast cells Generative AI
June 17th 2025

Prevalence of Dosage Modifications and Impact on Response Milestone Among Patients With CML Treated With Imatinib Using RWD

Natalie Hollon, PharmD Viet Dang, PharmD Candidate Grace Eramo, PhD Candidate Ravi Parekh, PharmD Candidate Janiyah Sutton, PharmD Angela Su, PharmD Candidate Ama Boamah, PharmD Candidate Eugene Lee, PharmD Kevin Chen, PharmD Yanguang Cao, PhD Benyam Muluneh, PharmD, CPP
Related Content
Advertisement
FDA - U.S Food & Drug Administration
June 18th 2025

Midyear Roundup: FDA’s Novel Oncology Drug Approvals in 2025

Luke Halpern, Assistant Editor
S2. Ep 56: Insights From a Pharmacy Times Peer Exchange: How to Talk the Talk
June 3rd 2025

S2. Ep 56: Insights From a Pharmacy Times Peer Exchange: How to Talk the Talk

Alexandra Gerlach, Associate Editor
Vector Representation of Acute Myeloid Leukemia Cells
June 18th 2025

Sequencing of Liposomal Daunorubicin/Cytarabine Versus Hypomethylating Agents Plus Venetoclax for Secondary Acute Myeloid Leukemia

Alan Flores, PharmD Jose Tinajero, PharmD, BCOP Dat Ngo, PharmD
Insights from a Pharmacy Times Peer Exchange: Toxicity Monitoring and Management in Real-World Settings
May 28th 2025

Insights from a Pharmacy Times Peer Exchange: Toxicity Monitoring and Management in Real-World Settings

Alexandra Gerlach, Associate Editor
Nurse -- Image credit: Rawpixel.com | stock.adobe.com
June 17th 2025

The Value of a Medically Integrated Pharmacy to Maximize Cost Avoidance and Reduce Waste of Oral Oncolytic Medications

Douglas Braun, PharmD, CSP, RPh
a microscope view of bone marrow showing the presence of abundant mast cells Generative AI
June 17th 2025

Prevalence of Dosage Modifications and Impact on Response Milestone Among Patients With CML Treated With Imatinib Using RWD

Natalie Hollon, PharmD Viet Dang, PharmD Candidate Grace Eramo, PhD Candidate Ravi Parekh, PharmD Candidate Janiyah Sutton, PharmD Angela Su, PharmD Candidate Ama Boamah, PharmD Candidate Eugene Lee, PharmD Kevin Chen, PharmD Yanguang Cao, PhD Benyam Muluneh, PharmD, CPP
Consent Preferences
About Us
Clinical Forums
Advertise
Contact Us
Editorial Staff
Privacy Policy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.